Aardvark Therapeutics, based in San Diego, CA, is a clinical stage biopharmaceutical company dedicated to restoring equilibrium through gut-brain therapeutics. They specialize in the development and commercialization of small molecule therapeutics with a wide range of therapeutic potential. At the core of their groundbreaking science is the exploration of bitter taste receptors known as Tas2Rs.

These receptors, found on various cells throughout the body, play a crucial role in monitoring potential toxins and triggering anti-toxin responses. Aardvark Therapeutics aims to leverage these receptors to deliver therapeutic benefits. Their lead product, ARD-101, is an oral drug designed to have low systemic exposure while activating gut peptide hormone secretion and gut-brain signaling.

It has demonstrated impressive results in preclinical and human clinical trials, exhibiting a broad safety window and efficacy in metabolic and inflammatory disease models. Aardvark Therapeutics is driven by a commitment to activating homeostatic pathways for disease treatment. Discover more about their pioneering approach by reaching out to them today